Low expressions of EHD2 and E-cadherin correlate with a poor prognosis for clear cell renal cell carcinoma.
10.11817/j.issn.1672-7347.2019.190098
- Author:
Mingji YE
1
,
2
;
Gang FAN
1
,
3
,
4
;
Shuai ZHU
1
,
2
;
Weiqing HAN
1
,
2
;
Yu XIE
1
,
2
Author Information
1. Department of Urology, Hunan Cancer Hospital
2. Affi liated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013.
3. Affi liated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013
4. Charité-Universitätsmedizin Berlin, Berlin 13125, Germany ).
- Publication Type:Journal Article
- MeSH:
Cadherins;
Carcinoma, Renal Cell;
Carrier Proteins;
Humans;
Kidney Neoplasms;
Neoplasm Staging;
Prognosis
- From:
Journal of Central South University(Medical Sciences)
2019;44(8):864-870
- CountryChina
- Language:Chinese
-
Abstract:
To explore roles of expressions of EHD2 and E-cadherin in clear cell renal cell carcinoma (ccRCC).
Methods: Four couples of fresh ccRCC tissues and adjacent non-cancerous tissues were collected to evaluate the expression of EHD2 and E-cadherin protein by Western blotting. A total of 65 paraffin-embedded renal ccRCC tissues were collected, and immunohistochemical assay was used to detect the expression of EHD2 and E-cadherin in the samples. The correlation between their expression and clinical and pathological indicators of ccRCC was analyzed, and the relationship between EHD2 and E-cadherin proteins and prognosis for patients with ccRCC was also explored.
Results: The results of Western blotting showed that the expression levels of EHD2 and E-cadherin were low in 4 ccRCC tissues compared with the adjacent noncancerous tissues. Immunohistochemical results revealed that the expressions of EHD2 and E-cadherin were higher in the localized ccRCC tissues than those in the metastatic ccRCC tissues; the expression levels of EHD2 and E-cadherin were decreased, while the TNM staging and Fuhrman grade were increased (P<0.05 or P<0.01). There was positive correlation between the expressions of EHD2 and E-cadherin in ccRCC (r=0.390, P<0.01). The progression-free survival in ccRCC patients with lower expression of both EHD2 and E-cadherin was better than that in ccRCC patients with higher expressions of EHD2 and E-cadherin (P<0.05).
Conclusion: The low expressions of EHD2 and E-cadherin are the potential indicators for the ccRCC patients with poor prognosis.
